Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RSV604 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RSV604 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects, 18-50 years of age, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * Vital signs within the following parameters: oral body temperature between 35...
RSV604 is an investigational small molecule drug developed by Novartis AG. It was studied in a Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics in healthy adult subjects. RSV604 has not been approved by the FDA and remains in early-stage clinical development.
RSV604 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 clinical trial of RSV604 conducted in the United Kingdom. The drug is an investigational small molecule and has not received regulatory approval.
RSV604 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug has not been approved by the FDA and remains investigational.
RSV604 has been studied in one completed Phase 1 clinical trial, NCT00416442, titled Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects. The trial enrolled 48 healthy adult participants in the United Kingdom and is now completed.
The Phase 1 trial NCT00416442 was a randomized, double-blind study of single and multiple intravenous doses of RSV604 in 48 healthy adult subjects. It was conducted in the United Kingdom and has been completed. The trial evaluated safety, tolerability, and pharmacokinetics.